Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and I...(eeded. To this end we havebeen intereste...),Health

Date:7/1/2008

eeded. To this end, we have been interested in identifying biomarkers for embryo viability and competence. Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth media only seen in competent embryos. These proteins may prove to be biomarkers that can enhance selection and result in more live births from single embryo transfers. These are very exciting results."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT to extract new proteins; the speed of sample preparation using PCT compared with other sample preparation methods; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins in cancer, stroke, and IVF samples; and the possibility that extraction of proteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced selection for single embryo transfers. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ m
'/>"/>

SOURCE Pressure BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
2. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
3. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
7. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
10. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
11. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges